Critical Care Ultrasound Oriented Shock Treatment in ICU

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03093987

Enrollment

150

Registered

2017-03-28

Start date

2017-04-05

Completion date

2017-10-28

Last updated

2017-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Shock

Keywords

Shock, Critical Care Ultrasound, Lactate, Mortality, Prognosis

Brief summary

Objective To investigate whether critical care ultrasound oriented shock management in shock patients in intensive care unit(ICU) can improve outcome. Methods Randomized controlled research. Patients were randomly allocated to two groups. In the critical care ultrasound oriented shock management group (CUSS group), treatment was oriented by the findings of critical care ultrasound in each shock phase, while in the control group the decisions about the monitoring and management were made by the clinical team. The goal of treatments in both groups were decreasing lactate by 20% or more per 2 hours for the Optimization phase in shock management, and no increase lactate level when removing the fluid in de-escalation phase. The primary outcome measure were hospital mortality and 28-day mortality, the secondary outcome measure were the length of ventilation and the length of ICU stay.

Interventions

OTHERCritical care ultrasound

Circulateory will be managed according to the result of critical ultrasound joint clearance of lactic acid in patients with shock

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* SBP \<90 mm Hg or MAP \<65 mm Hg or SBP decrease \>40mmHg or need vasoactive drugs； * Skin that is cold and clammy，capillary refill time \>4.5s，urine output of\<0.5ml/Kg.hr and lactate \>2mmol/L； * SHOCK presented within 6 hr.

Exclusion criteria

* \<18 years old； * Pregnancy； * Patient or family member refuse to be enrolled.

Design outcomes

Primary

Measure	Time frame	Description
28-day mortality	through study completion,an average of 28 days	28-day mortality

Secondary

Measure	Time frame	Description
the length of ICU stay	through study completion,an average of 28 days	the length of ICU stay
the total length of hospital stay	through study completion,an average of 28 days	the total length of hospital stay
the incidence of AKI	through study completion,an average of 28 days	the incidence of AKI

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026